To study melanoma-intrinsic CM-272 effects, MO4 cells were first exposed to the drug in vitro. H3K9me2- and 5mC-levels were significantly reduced upon treatment, suggesting G9a and DNMT1 to be active in MO4 tumors and inhibitable by CM-272 (Figure 1A). Here, DNMT1 is linked to melanoma.